Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 50Melanoma 23Neoplasms 19Neoplasm Metastasis 19Squamous Cell Carcinoma of Head and Neck 17Lung Neoplasms 13Skin Neoplasms 12Recurrence 10Head and Neck Neoplasms 10Carcinoma, Renal Cell 9Prostatic Neoplasms 8Ovarian Neoplasms 8Colorectal Neoplasms 8Carcinoma, Squamous Cell 8Carcinoma, Basal Cell 8Breast Neoplasms 8Urinary Bladder Neoplasms 7Carcinoma, Merkel Cell 7Triple Negative Breast Neoplasms 6Colonic Neoplasms 6Carcinoma 6Adenocarcinoma 6Uterine Cervical Neoplasms 5Sarcoma 5Pancreatic Neoplasms 5Glioblastoma 5Stomach Neoplasms 4Multiple Myeloma 4Mouth Neoplasms 4Fallopian Tube Neoplasms 4

Interventions

Temozolomide 26Magnetic Resonance Spectroscopy 19Etoposide 14Cyclophosphamide 13Radiotherapy 11Filgrastim 10Bevacizumab 10Carboplatin 9Biopsy 8Cisplatin 7X-Rays 6Thiotepa 6Specimen Handling 6Phantoms, Imaging 6Carmustine 6Radiation 5Nuclear Medicine Department, Hospital 5Nivolumab 5Irinotecan 52-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 5sargramostim 4Vincristine 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4Erlotinib Hydrochloride 4Azacitidine 4olaparib 3etoposide phosphate 3Surveys and Questionnaires 3Surgical Procedures, Operative 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ependymoma × cemiplimab × Clear all
NCT07567469 2026-05-05

A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma

Regeneron Pharmaceuticals

Phase 1/2 Not yet recruiting
120 enrolled
CNS

Ependymoma, Glioma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡